Karyopharm therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Newton, mass. , feb. 1, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the company granted an aggregate of 26,850 restricted stock units (rsus) to seven newly-hired employees.
KPTI Ratings Summary
KPTI Quant Ranking